Assessment of Pediatric Admissions for Kawasaki Disease or Infectious Disease During the COVID-19 State of Emergency in Japan.


Journal

JAMA network open
ISSN: 2574-3805
Titre abrégé: JAMA Netw Open
Pays: United States
ID NLM: 101729235

Informations de publication

Date de publication:
01 04 2021
Historique:
entrez: 6 4 2021
pubmed: 7 4 2021
medline: 21 4 2021
Statut: epublish

Résumé

The development of Kawasaki disease (KD) has been suggested to be associated with droplet- or contact-transmitted infection; however, its triggers and transmission modes remain to be determined. Under an epidemic of SARS-CoV-2, the COVID-19 state of emergency in Japan served as a nationwide social experiment to investigate the impact of quarantine or isolation on the incidence of KD. To assess the role of droplet or contact transmission in the etiopathogenesis of KD. This multicenter, longitudinal, cross-sectional study was conducted from 2015 to 2020 at Fukuoka Children's Hospital and 5 adjacent general hospitals. The number of admissions for KD and infectious diseases were analyzed. Participants were pediatric patients admitted to the participating hospitals for KD or infectious diseases. Quarantine and isolation owing to the COVID-19 state of emergency. The primary end points were the ratios of patients with KD to patients with respiratory tract or gastrointestinal infections admitted from April to May in 2015 to 2019 and 2020. A Poisson regression model was used to analyze them. The study participants included 1649 patients with KD (median [interquartile range] age, 25 [13-43] months; 901 boys [54.6%]) and 15 586 patients with infectious disease (data on age and sex were not available for these patients). The number of admissions for KD showed no significant change between April and May in 2015 to 2019 vs the same months in 2020 (mean [SD], 24.8 [5.6] vs 18.0 [4.0] admissions per month; 27.4% decrease; adjusted incidence rate ratio [aIRR], 0.73; 95% CI, 0.48-1.10; P = .12). However, the number of admissions for droplet-transmitted or contact-transmitted respiratory tract infections (mean [SD], 157.6 [14.4] vs 39.0 [15.0] admissions per month; 75.3% decrease; aIRR, 0.25; 95% CI, 0.17-0.35; P < .001) and gastrointestinal infections (mean [SD], 43.8 [12.9] vs 6.0 [2.0] admissions per month; 86.3% decrease; aIRR, 0.14; 95% CI, 0.04-0.43; P < .001) showed significant decreases between April and May in 2015 to 2019 vs the same months in 2020 (total, 12 254 infections). Thus, the ratio of KD to droplet- or contact-transmitted respiratory tract and gastrointestinal infections incidence in April and May 2020 was significantly increased (ratio, 0.40 vs 0.12; χ21 = 22.76; P < .001). In this study, the significantly increased incidence of KD compared with respiratory tract and gastrointestinal infections during the COVID-19 state of emergency suggests that contact or droplet transmission is not a major route for KD development and that KD may be associated with airborne infections in most cases.

Identifiants

pubmed: 33822065
pii: 2778178
doi: 10.1001/jamanetworkopen.2021.4475
pmc: PMC8025113
doi:

Types de publication

Journal Article Multicenter Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e214475

Commentaires et corrections

Type : CommentIn
Type : ErratumIn

Références

PLoS One. 2014 Nov 20;9(11):e113054
pubmed: 25411968
Hawaii Med J. 2010 Aug;69(8):194-7
pubmed: 20845285
Pediatr Infect Dis J. 2010 Aug;29(8):770-2
pubmed: 20354462
Ann Rheum Dis. 2020 Aug;79(8):999-1006
pubmed: 32527868
Proc Natl Acad Sci U S A. 2014 Jun 3;111(22):7952-7
pubmed: 24843117
J Pediatr. 2016 Oct;177:179-183.e1
pubmed: 27496266
Lancet Child Adolesc Health. 2020 Sep;4(9):662-668
pubmed: 32622376
JAMA. 2020 Jul 21;324(3):259-269
pubmed: 32511692
Pediatr Infect Dis J. 2007 Jul;26(7):629-31
pubmed: 17596806
N Engl J Med. 2020 Jul 23;383(4):334-346
pubmed: 32598831
Yonsei Med J. 2016 Jan;57(1):15-21
pubmed: 26632378
J Infect Dis. 2005 Feb 15;191(4):499-502
pubmed: 15655771
Phys Fluids (1994). 2020 Dec 1;32(12):127112
pubmed: 33362404
Pediatr Cardiol. 2018 Feb;39(2):207-225
pubmed: 29098351
PLoS One. 2018 Feb 7;13(2):e0191087
pubmed: 29415012
Lancet. 2020 May 2;395(10234):1417-1418
pubmed: 32325026
BMJ. 2020 Jun 3;369:m2094
pubmed: 32493739
Pediatr Infect Dis J. 2011 Dec;30(12):1114-6
pubmed: 21796015
Sci Rep. 2011;1:152
pubmed: 22355668
Arerugi. 1967 Mar;16(3):178-222
pubmed: 6062087
Cardiovasc Res. 2021 Jan 1;117(1):96-108
pubmed: 31782770
Int J Rheum Dis. 2018 Jan;21(1):26-30
pubmed: 29152908
Med Hypotheses. 2007;69(3):642-51
pubmed: 17337130
Circulation. 2020 Jul 7;142(1):68-78
pubmed: 32293910
Circulation. 2017 Apr 25;135(17):e927-e999
pubmed: 28356445
J Formos Med Assoc. 2014 Mar;113(3):148-54
pubmed: 24495555
Nat Rev Immunol. 2020 Jun;20(6):375-388
pubmed: 32132681
Lancet. 1990 May 5;335(8697):1047-50
pubmed: 1970369
Proc Natl Acad Sci U S A. 2020 Aug 11;117(32):18984-18990
pubmed: 32723816
Lancet. 2020 Jun 6;395(10239):1771-1778
pubmed: 32410760
Pediatr Infect Dis J. 2005 Nov;24(11):1011-4
pubmed: 16282942
J Epidemiol. 2012;22(2):79-85
pubmed: 22307434
Jpn J Infect Dis. 2020 Sep 24;73(5):391-393
pubmed: 32350228
Br J Biomed Sci. 2001;58(2):122-8
pubmed: 11440204
N Engl J Med. 2020 Jul 23;383(4):347-358
pubmed: 32598830
Front Pediatr. 2019 Jun 28;7:244
pubmed: 31316950
Contrib Microbiol Immunol. 1991;12:292-6
pubmed: 1935106
Int J Environ Res Public Health. 2020 Feb 27;17(5):
pubmed: 32120916
BMC Pediatr. 2015 Nov 11;15:177
pubmed: 26561332
JAMA. 2020 Jul 21;324(3):294-296
pubmed: 32511676
Acta Paediatr. 2006 Dec;95(12):1661-4
pubmed: 17129979
J Virol. 1992 May;66(5):3206-9
pubmed: 1348548
Pediatr Infect Dis. 1983 Mar-Apr;2(2):123-6
pubmed: 6344044
Clin Exp Immunol. 2016 Nov;186(2):134-143
pubmed: 27342882
J Med Virol. 1990 Sep;32(1):53-7
pubmed: 2173738
Nat Rev Immunol. 2020 Jun;20(6):363-374
pubmed: 32346093
Environ Sci Pollut Res Int. 2019 Dec;26(34):34741-34753
pubmed: 31654301
Pediatrics. 2020 Aug;146(2):
pubmed: 32439816
J Environ Public Health. 2020 May 28;2020:1646943
pubmed: 32565838
Environ Int. 2015 May;78:32-38
pubmed: 25743034
Pediatrics. 1989 Oct;84(4):666-9
pubmed: 2780128

Auteurs

Takuya Hara (T)

Kawasaki Disease Center, Fukuoka Children's Hospital, Kashiiteriha, Higashi-ku, Fukuoka, Japan.

Kenji Furuno (K)

Kawasaki Disease Center, Fukuoka Children's Hospital, Kashiiteriha, Higashi-ku, Fukuoka, Japan.

Kenichiro Yamamura (K)

Department of Perinatal and Pediatric Medicine, Graduate School of Medical Sciences, Kyushu University, Maidashi, Higashi-ku, Fukuoka, Japan.

Junji Kishimoto (J)

Department of Research and Development of Next Generation Medicine, Faculty of Medical Sciences, Kyushu University, Maidashi, Higashi-ku, Fukuoka, Japan.

Yumi Mizuno (Y)

Kawasaki Disease Center, Fukuoka Children's Hospital, Kashiiteriha, Higashi-ku, Fukuoka, Japan.

Kenji Murata (K)

Kawasaki Disease Center, Fukuoka Children's Hospital, Kashiiteriha, Higashi-ku, Fukuoka, Japan.

Sagano Onoyama (S)

Division of Pediatrics, Japanese Red Cross Fukuoka Hospital, Ookusu, Minami-Ku, Fukuoka, Japan.

Ken Hatae (K)

Division of Pediatrics, Japanese Red Cross Fukuoka Hospital, Ookusu, Minami-Ku, Fukuoka, Japan.

Megumi Takemoto (M)

Division of Pediatrics, Hamanomachi Hospital, Nagahama, Chuo-ku, Fukuoka, Japan.

Yoshito Ishizaki (Y)

Division of Pediatrics, National Hospital Organization Fukuokahigashi Medical Center, Chidori, Koga, Fukuoka, Japan.

Shunsuke Kanno (S)

Division of Pediatrics, National Hospital Organization Kyushu Medical Center, Jigyohama, Chuo-ku, Fukuoka, Japan.

Kazuo Sato (K)

Division of Pediatrics, National Hospital Organization Kyushu Medical Center, Jigyohama, Chuo-ku, Fukuoka, Japan.

Yoshitomo Motomura (Y)

Department of Pediatrics, Graduate School of Medical Sciences, Kyushu University, Maidashi, Higashi-ku, Fukuoka, Japan.

Yasunari Sakai (Y)

Department of Pediatrics, Graduate School of Medical Sciences, Kyushu University, Maidashi, Higashi-ku, Fukuoka, Japan.

Shouichi Ohga (S)

Department of Pediatrics, Graduate School of Medical Sciences, Kyushu University, Maidashi, Higashi-ku, Fukuoka, Japan.

Mayumi Yashiro (M)

Department of Public Health, Jichi Medical University, Yakushiji, Shimotsuke, Tochigi, Japan.

Yoshikazu Nakamura (Y)

Department of Public Health, Jichi Medical University, Yakushiji, Shimotsuke, Tochigi, Japan.

Toshiro Hara (T)

Kawasaki Disease Center, Fukuoka Children's Hospital, Kashiiteriha, Higashi-ku, Fukuoka, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH